EUVIMEDEUVIMED entdecken
Crossref

Trends in Initiation of Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among Commercially Insured Adults in the United States, 2001–2021

Lydia Y Lee, Jeffrey A Sparks, Priyanka Yalamanchili, Daniel B Horton, Zeba M Khan, Joseph Barone, Chintan V Dave

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025-09 · 45 (9) · 578-586

DOI: 10.1002/phar.70051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 12.08.2025. Verfasst von Lydia Y Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Health Outcomes, Policy & Economics, Rutgers Ernest Mario School of Pharmacy and Rutgers School of Public Health, Piscataway, New Jersey, …. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate patterns in disease‐modifying antirheumatic drugs ( DMARDs ) initiations between 2001 and 2021 among adults with Rheumatoid Arthritis ( RA ) in the United States Methods This retrospective cohort study used a US commercial claims database (2001–2021) to identify patients (≥ 18 years) with RA newly initiating a DMARD . We calculated the annual proportion of initiations for 22 DMARDs , categorized as conventional synthetic ( csDMARDs ), biologic ( bDMARDs ), and targeted synthetic ( tsDMARDs ). Secondary analyses examined trends in first‐line non‐ csDMARD initiation and biosimilar uptake.

Results

We identified 407,728 DMARD initiation episodes among 229,365 unique patients with RA (median age: 50 years [ IQR ], 44–58 years; 79.4% female). There were shifts in DMARD initiations, with csDMARD initiation declining from 79.9% of initiations in 2001 to 54.7% by 2021 ( p < 0.001 for trend). Meanwhile, bDMARDs and tsDMARDs initiations increased from 20.3% in 2001 to 33.1% in 2021 ( p < 0.001) and from 0.1% in 2012 to 12.2% in 2021 ( p = 0.171), respectively. Methotrexate remained the most initiated DMARD over the 21‐year study period, albeit declining from 28.7% to 15.0% of initiations over the study period ( p < 0.001). Adalimumab was the most frequently initiated bDMARD (13.3% in 2003 and 12.2% in 2021; p = 0.05). Among tsDMARDs , tofacitinib initiation peaked at 8.9% in 2019 and declined to 4.4% in 2021, while upadacitinib initiation increased from 1.2% to 7.6% during the same period ( p < 0.001). For secondary analyses, adalimumab was the predominant first‐line b/ tsDMARD initiated (> 40%). Biosimilar uptake stayed below 1%.

Conclusion

Expanded DMARD options over the last two decades have led to decreased csDMARD initiations and increased b/ tsDMARD initiations, reflecting patient‐ and system‐level factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, RheumatoidHumansFemaleUnited StatesRetrospective StudiesAdultMiddle AgedMaleBiosimilar PharmaceuticalsCohort StudiesDatabases, FactualBiological Products

Stichwörter der Autor:innen

antirheumatic agents/utilizationbiological products/therapeutic usedisease‐modifying antirheumatic drugsdrug utilization reviewhealth care trendsrheumatoid arthritis

Substanzen

Antirheumatic AgentsBiosimilar PharmaceuticalsBiological Products

Autor:innen und Institutionen

  • Center for Health Outcomes, Policy & Economics, Rutgers Ernest Mario School of Pharmacy and Rutgers School of Public Health, Piscataway, New Jersey, USA.
  • Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, New Jersey, USA.
  • Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey, USA.
  • Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Rutgers University, Piscataway, New Jersey, USA.
  • Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey, USA.

Zitieren

APA

Lee, L. Y., Sparks, J. A., Yalamanchili, P., Horton, D. B., Khan, Z. M., Barone, J., & Dave, C. V. (2025). Trends in Initiation of Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among Commercially Insured Adults in the United States, 2001–2021. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 45(9), 578-586. https://doi.org/10.1002/phar.70051

Vancouver

Lee LY, Sparks JA, Yalamanchili P, Horton DB, Khan ZM, Barone J, et al. Trends in Initiation of Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among Commercially Insured Adults in the United States, 2001–2021. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025;45(9):578-586. doi:10.1002/phar.70051

BibTeX
@article{Lee2025,
  author = {Lee, Lydia Y and Sparks, Jeffrey A and Yalamanchili, Priyanka and Horton, Daniel B and Khan, Zeba M and Barone, Joseph and Dave, Chintan V},
  title = {Trends in Initiation of Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among Commercially Insured Adults in the United States, 2001–2021},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2025},
  volume = {45},
  number = {9},
  pages = {578--586},
  doi = {10.1002/phar.70051}
}
Kostenlos starten →